任天堂
吡非尼酮
医学
特发性肺纤维化
不利影响
间质性肺病
肺功能
肺纤维化
肺
内科学
肺功能测试
肺纤维化
纤维化
作者
Katyayini Aribindi,Gabrielle Y. Liu,Timothy E. Albertson
标识
DOI:10.1080/17512433.2024.2396121
摘要
Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive-fibrosing lung disease with a median survival of less than 5 years. Currently, two agents, pirfenidone and nintedanib are approved for this disease, and both have been shown to reduce the rate of decline in lung function in patients with IPF. However, both have significant adverse effects and neither completely arrest the decline in lung function.
科研通智能强力驱动
Strongly Powered by AbleSci AI